Kintegral Advisory LLC Lowers Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Kintegral Advisory LLC lessened its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 32.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,302 shares of the medical equipment provider's stock after selling 4,073 shares during the period. Kintegral Advisory LLC's holdings in Zimmer Biomet were worth $942,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Franklin Resources Inc. boosted its holdings in shares of Zimmer Biomet by 398.7% during the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock worth $369,469,000 after buying an additional 2,796,372 shares during the period. Norges Bank acquired a new position in Zimmer Biomet during the 4th quarter worth approximately $216,223,000. Dodge & Cox grew its holdings in Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock worth $2,019,480,000 after acquiring an additional 2,044,645 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Zimmer Biomet by 191.8% in the 4th quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider's stock valued at $146,763,000 after purchasing an additional 913,310 shares during the last quarter. Finally, Sound Shore Management Inc. CT bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at $81,447,000. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

NYSE ZBH traded up $0.91 on Tuesday, reaching $93.48. 976,939 shares of the stock were exchanged, compared to its average volume of 1,810,898. The firm has a market capitalization of $18.50 billion, a PE ratio of 20.68, a PEG ratio of 2.17 and a beta of 0.71. The company has a current ratio of 2.44, a quick ratio of 1.46 and a debt-to-equity ratio of 0.53. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $116.71. The company's 50-day simple moving average is $93.85 and its two-hundred day simple moving average is $101.63.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The company had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. During the same quarter in the previous year, the business posted $1.94 earnings per share. Zimmer Biomet's quarterly revenue was up 1.1% on a year-over-year basis. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.03%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's payout ratio is 21.24%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Stifel Nicolaus set a $115.00 target price on shares of Zimmer Biomet and gave the company a "buy" rating in a research report on Tuesday, May 6th. BTIG Research reaffirmed a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. JMP Securities dropped their price objective on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Truist Financial set a $101.00 price objective on shares of Zimmer Biomet in a research note on Tuesday, May 6th. Finally, Raymond James Financial dropped their price target on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $110.56.

Insider Buying and Selling

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of Zimmer Biomet stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the transaction, the insider directly owned 20,424 shares of the company's stock, valued at $1,940,280. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.70% of the stock is owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.